Paragraph 1
A new
of game-changing weight-loss drugs could be launched next year. One
is being dubbed "Ozempic 2.0". This is a pill
of the widely-used Ozempic. Novo Nordisk, which is developing the
tablet, said its clinical trials showed that Ozempic 2.0 "lowered
by an average of 10.5 per cent". Rival
Eli Lilly also has a new pill. Its
, Kenneth Custer, said: "We are moving with urgency toward
regulatory submissions to potentially meet the needs of
." The drugs are currently awaiting
from the FDA in the USA.
